Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The beta-agonist controversy

D R Taylor1, M R Sears, D W Cockcroft

  • 1Department of Medicine, University of Otago Medical School, Dunedin, New Zealand.

The Medical Clinics of North America
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A dual CysLT<sub>1/2</sub> antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma.

Allergy·2016
Same author

Indoor mold levels and current asthma among school-aged children in Saskatchewan, Canada.

Indoor air·2016
Same author

Measurement of serum 7α-hydroxy-4-cholesten-3-one as a marker of bile acid malabsorption in dogs with chronic diarrhoea: a pilot study.

Veterinary record open·2016
Same author

Recent admixture generates heterozygosity-fitness correlations during the range expansion of an invading species.

Journal of evolutionary biology·2015
Same author

Allergen-induced early and late asthmatic responses to inhaled seasonal and perennial allergens.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Airway responsiveness to mannitol 24 h after allergen challenge in atopic asthmatics.

Allergy·2015
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Long-term use of short-acting beta-agonists is linked to increased asthma deaths and worsening symptoms. Anti-inflammatory therapy is preferred for chronic asthma management, while beta-agonists are for acute relief.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Epidemiology

Background:

  • The asthma paradox, characterized by increasing morbidity and mortality despite advancements, has prompted re-evaluation of therapeutic strategies.
  • Pharmacoepidemiologic studies suggest a correlation between elevated short-acting beta-agonist (SABA) use and asthma-related fatalities, independent of disease severity.
  • Clinical evidence indicates limited long-term benefits and potential adverse effects associated with prolonged SABA therapy.

Purpose of the Study:

  • To investigate the role of short-acting inhaled beta-agonist drugs in asthma management.
  • To explain the asthma paradox by examining the long-term effects of beta-agonist use.
  • To propose revised therapeutic guidelines for beta-agonist utilization in asthma.

Main Methods:

Related Experiment Videos

  • Review of pharmacoepidemiologic studies linking beta-agonist use to asthma mortality.
  • Analysis of clinical trial data on the efficacy and safety of long-term beta-agonist therapy.
  • Examination of mechanistic investigations exploring the impact of beta-agonists on bronchial responsiveness.

Main Results:

  • Strong association found between increased SABA use and asthma deaths, not fully explained by confounding factors.
  • Limited evidence of symptomatic or functional improvement with long-term SABA use; significant adverse effects noted.
  • Potential mechanisms, including increased bronchial hyperresponsiveness, identified to explain adverse findings.

Conclusions:

  • Regular or long-term use of SABAs is inappropriate for chronic asthma management.
  • Adequate anti-inflammatory therapy is the preferred treatment for chronic asthma.
  • SABAs remain crucial for acute exacerbations, breakthrough symptoms, and exercise-induced asthma prophylaxis.